Literature DB >> 28733172

SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System.

Gian Paolo Fadini1, Angelo Avogaro2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28733172     DOI： 10.1016/S2213-8587(17)30257-7

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  40 in total

1.  Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.

Authors:  Masayuki Kaneko; Mamoru Narukawa
Journal:  Clin Drug Investig       Date:  2019-02       Impact factor: 2.859

2.  Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use.

Authors:  Louis Potier; Ronan Roussel; Gilberto Velho; Pierre-Jean Saulnier; Anisoara Bumbu; Odette Matar; Fabrice Schneider; Stéphanie Ragot; Michel Marre; Kamel Mohammedi; Samy Hadjadj
Journal:  Diabetologia       Date:  2019-02-26       Impact factor: 10.122

3.  Canagliflozin should be prescribed with caution to individuals with type 2 diabetes and high risk of amputation.

Authors:  Matilde Monteiro-Soares; Inês Ribeiro-Vaz; Edward J Boyko
Journal:  Diabetologia       Date:  2019-04-02       Impact factor: 10.122

Review 4.  Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?

Authors:  Rosalie A Scholtes; Michaël J B van Baar; Yuliya Lytvyn; Petter Bjornstad; Max Nieuwdorp; David Z I Cherney; Daniël H van Raalte
Journal:  Diabetes Obes Metab       Date:  2019-04       Impact factor: 6.577

Review 5.  Canagliflozin: A Review in Type 2 Diabetes.

Authors:  Emma D Deeks; André J Scheen
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

6.  The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study.

Authors:  Stuart J McGurnaghan; Liam Brierley; Thomas M Caparrotta; Paul M McKeigue; Luke A K Blackbourn; Sarah H Wild; Graham P Leese; Rory J McCrimmon; John A McKnight; Ewan R Pearson; John R Petrie; Naveed Sattar; Helen M Colhoun
Journal:  Diabetologia       Date:  2019-01-10       Impact factor: 10.122

Review 7.  Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney
Journal:  Circulation       Date:  2017-10-24       Impact factor: 29.690

Review 8.  The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.

Authors:  Jonathan D Newman; Anish K Vani; Jose O Aleman; Howard S Weintraub; Jeffrey S Berger; Arthur Z Schwartzbard
Journal:  J Am Coll Cardiol       Date:  2018-10-09       Impact factor: 24.094

9.  Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.

Authors:  Hafiz Imran; William Nester; Islam Y Elgendy; Marwan Saad
Journal:  Ann Med       Date:  2020-05-22       Impact factor: 4.709

10.  2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.

Authors:  Sandeep R Das; Brendan M Everett; Kim K Birtcher; Jenifer M Brown; James L Januzzi; Rita R Kalyani; Mikhail Kosiborod; Melissa Magwire; Pamela B Morris; Joshua J Neumiller; Laurence S Sperling
Journal:  J Am Coll Cardiol       Date:  2020-08-05       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.